1. Scrip

China Approval For Akeso’s Bispecific But ASCO Data Unnerve Investors

 
• By Dexter Jie Yan

Ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 54% versus placebo in EGFR-mutated, non-squamous NSCLC after failed EGFR inhibitor treatment. However, the progression-free survival data did little to satisfy investors’ demand for clear benefits versus competitors. 

China pharma US trial
Akeso's ivonescimab faces twisty road to efficacy superiority over rivals • Source: Shutterstock

Akeso Inc. has snagged a world-first approval, in China, for ivonescimab, its first-in-class PD-1/VEGF-targeting bispecific antibody.

But the glitter of the breakthrough was dimmed by investors’ alleged concerns over efficacy data from the Phase III trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia